ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies

[MEDPAGE TODAY]( Oncology Update Friday, January 27, 2023 [ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies]( [Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patients]( [New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia A]( [MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies]( [FDA OKs Adjuvant Pembrolizumab for NSCLC]( ADVERTISEMENT Exclusives & Features [Medicare Part D Plan Prices May Change Unexpectedly]( [Is ChatGPT Becoming Synonymous With Plagiarism in Scientific Research?]( [Here's Why 'Thanks Pfizer' Is Trending on Social Media]( [The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada.]( PURPOSE: Survivors of childhood medulloblastoma suffer from substantial late effects. We characterized these sequelae using real-world health services data in a population-based cohort of... [READ MORE]( [Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia.]( Acute myeloid leukemia (AML) outcomes are very poor in older patients. Haploidentical stem cell transplantation (haplo-SCT) helps to achieve long-term survival. However, the benefit of haplo-SCT... [READ MORE]( [Performance of statistical and machine learning risk prediction models for surveillance benefits and failures in breast cancer survivors.]( Background Machine learning (ML) approaches facilitate risk prediction model development using high-dimensional predictors and higher-order interactions at the cost of model interpretability and... [READ MORE]( [Tumor micronecrosis predicts poor prognosis of patients with hepatocellular carcinoma after liver transplantation.]( BACKGROUND: Tumor micronecrosis is a histopathological feature predicting poor prognosis in patients with hepatocellular carcinoma (HCC) who underwent liver resection. However, the role of tumor... [READ MORE]( [Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.]( Chimeric antigen receptor (CAR) T cell therapy has shown success in the treatment of hematopoietic malignancies; however, relapse remains a significant issue. To overcome this, we engineered "Orexi"... [READ MORE]( [A Property of Everyday Health group]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2023-01-27&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 345 Hudson Street 16th Floor New York, NY 10014